2012 Immunotherapy could be answer to treating novel coronavirus

上传人:麦**** 文档编号:141704772 上传时间:2020-08-11 格式:PDF 页数:2 大小:59.71KB
返回 下载 相关 举报
2012 Immunotherapy could be answer to treating novel coronavirus_第1页
第1页 / 共2页
2012 Immunotherapy could be answer to treating novel coronavirus_第2页
第2页 / 共2页
亲,该文档总共2页,全部预览完了,如果喜欢就下载吧!
资源描述

《2012 Immunotherapy could be answer to treating novel coronavirus》由会员分享,可在线阅读,更多相关《2012 Immunotherapy could be answer to treating novel coronavirus(2页珍藏版)》请在金锄头文库上搜索。

1、Springer Healthcare News Immunotherapy could be answer to treating novel coronavirus Published online: 20 February 2013 Springer Healthcare 2013 medwireNews: Investigation into the mechanism of action of the novel coronavirus HCoV-EMC, which recently emerged in the Middle East, has revealed that alt

2、hough human bronchial epithelia are very susceptible to infection with the virus, interferon I and III were both able to significantly reduce its replication in cell culture. HCoV-EMC is associated with similar symptoms to severe acute respiratory syndrome (SARS), such as fever, cough, and breathing

3、 difficulties. It is also believed to have a zoonotic origin, because it is closely related to bat coronaviruses. Human airway epithelium (HAE) is a common infection target for respiratory viruses. Using an HAE cell culture, Ronald Dijkman (Institute of Immunobiology, Kantonal Hospital, St Gallen, S

4、witzerland) and colleagues investigated the mechanism of infection of HCoV-EMC and assessed possible treatments for the virus. HCoV-EMC was easily able to infect the HAE cells and “like other coronaviruses, evades innate immune recognition, reflected by the lack of interferon and minimal inflammator

5、y cytokine expression following infection,” write Dijkman and team in mBio. Notably, treatment with interferon I and III cytokines able to interfere with the replication of certain viruses significantly reduced the viral load in the infected HAE cells. The researchers hope their findings will help s

6、cientists develop a treatment for HCoV-EMC. To date, only 12 cases of the virus have been confirmed in the laboratory (five in Saudi Arabia, four in the UK, two in Jordan, and one in Germany), although co-author of the study Volker Thiel, also from the Institute of Immunobiology at the Kantonal Hosp

7、ital, believes more people may be infected. “We dont know whether the cases we observe are the tip of the iceberg,” says Thiel in a press statement. “Or whether many more people are infected without showing severe symptoms.” The latest case, reported in a family member of someone who developed the v

8、irus after traveling to the Middle East, seems to be a result of human-to-human infection, because the patient had not recently travelled out of the UK. John Watson, head of the respiratory diseases department at the Health Protection Agency (HPA) in the UK, told the press: “Although this case appea

9、rs to be due to person-to-person transmission, the risk of infection in contacts in most circumstances is still considered to be low.” He added that if the virus were more infectious “we would have expected to have seen a larger number of cases than we have seen since the first case was reported thr

10、ee months ago.” Concern has been expressed that HCoV-EMC could cause an epidemic like the 20022003 SARS epidemic, which infected more than 8000 individuals and caused almost 800 deaths. The small number of cases since the first reported infection in June 2012 suggests this is an unlikely scenario, but agencies such as the HPA and the World Health Organization (WHO) remain vigilant. By Helen Albert, Senior medwireNews Reporter Reference mBio 2013; 4: e0061112

展开阅读全文
相关资源
正为您匹配相似的精品文档
相关搜索

最新文档


当前位置:首页 > 研究生/硕士 > 专业课

电脑版 |金锄头文库版权所有
经营许可证:蜀ICP备13022795号 | 川公网安备 51140202000112号